Home / News

News

FDA Grants Fast Track designation to IVS-3001, Invectys...

FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma   Houston, TX, USA, July 31, 2023 – Invectys,…

Read more

Invectys Announces Initiation of Phase 1/2a Clinical Tr...

Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership Houston, TX, USA, July 13, 2023 – Invectys, Inc., a clinical-stage…

Read more

Invectys Receives its Second MATWIN Award

Invectys awarded “2023 Best Translational Development” by the MATWIN international Board   Houston, TX, USA, May 26, 2023 – Invectys Inc., a clinical-stage…

Read more

Invectys to participate in project Melomanes

Invectys is part of project “Melomanes”! Melomanes is a multidisciplinary project, which aims to develop a novel combination treatment for metastatic melanoma,…

Read more

INVECTYS, INC. TO PARTICIPATE IN THE 41ST JP MORGAN HEA...

INVECTYS, INC. TO PARTICIPATE IN THE 41ST JP MORGAN HEALTHCARE CONFERENCE ON JANUARY 9-12, 2023   Houston, Texas, January 5, 2023 – Invectys, Inc. “Invectys”,…

Read more

Invectys and CTMC Announce FDA Clearance of IND Applica...

Invectys and CTMC Announce FDA Clearance of IND Application for Anti-HLA-G CAR-T Cell Therapy   FDA granted IND clearance for IVS-3001, Invectys’s lead…

Read more

François Lescure, General Manager of Invectys SAS, to ...

FRANÇOIS LESCURE, GENERAL MANAGER OF INVECTYS SAS, TO PARTICIPATE IN THE ABBVIE PARTNERING DAY IN PARIS, FRANCE ON OCTOBER 4TH, 2022   Paris, France, September…

Read more

Invectys Inc. to Participate in the 9TH International C...

  9th International Conference on HLA-G July 4th – 5th 2022 Fondation Singer-Polignac, 43 Avenue Georges Mandel, 75116 Paris     Invectys will be…

Read more